Thompson Davis & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Thompson Davis & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,150	Closed	-$241K	–	149
2021 Q4	$241K	Buy	+2,150	New	+$259K	0.2%	87
2018 Q3	$380K	Buy	3,960 +625	+19%	+$60.6K	0.83%	26
2018 Q2	$317K	Hold	3,335	–	–	0.75%	34
2018 Q1	$293K	Buy	3,335 +85	+3%	+$7.76K	0.77%	32
2017 Q4	$276K	Sell	3,250 -2,002	-38%	-$168K	0.65%	31
2017 Q3	$455K	Buy	5,252 +1,126	+27%	+$90.3K	0.81%	20
2017 Q2	$318K	Buy	4,126 +1,876	+83%	+$133K	0.51%	49
2017 Q1	$156K	Buy	2,250 +2,000	+800%	+$134K	0.22%	96
2016 Q4	$15K	Hold	250	–	–	0.02%	598
2016 Q3	$17K	Hold	250	–	–	0.03%	533
2016 Q2	$14K	Buy	250 +125	+100%	+$6.85K	0.02%	569
2016 Q1	$6K	Sell	125 -500	-80%	-$26K	0.01%	760
2015 Q4	$44K	Buy	+625	New	+$42.6K	0.06%	283

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Thompson Davis & Co's XBI Position: Q1 2022 in Review

Thompson Davis & Co sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 2,150 shares — an estimated $241K sold.

Thompson Davis & Co first reported a position in XBI in Q4 2015 and held it in 13 quarters. The position peaked at $455K in Q3 2017. 702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Thompson Davis & Co reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Thompson Davis & Co sold 2,150 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $241K.
Thompson Davis & Co first reported a position in State Street SPDR S&P Biotech ETF in Q4 2015 and held it in 13 quarters.
Thompson Davis & Co's State Street SPDR S&P Biotech ETF position peaked at $455K in Q3 2017.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Thompson Davis & Co's 13F filing for Q1 2022, filed 13 May 2022.